Condition
Telangiectasias
Total Trials
4
Recruiting
1
Active
1
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
25%
1 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (3)
P 4 (1)
Trial Status
Completed2
Unknown1
Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT07678697Not ApplicableRecruiting
Nd:YAG Laser Combined With Injection Sclerotherapy Versus Diode Laser in the Treatment of Reticular Veins and Telangiectasias Using CLaCS Technique
NCT06962813Not ApplicableCompleted
Transdermal Radiofrequency V ERASER Versus Polidocanol Sclerotherapy for Reticular Veins and Telangiectasias
NCT02761174Phase 4CompletedPrimary
Topical Brimonidine to Reduce Inflammation After IPL-treatment in Patients With Facial Telangiectasias
NCT01118390Not ApplicableUnknownPrimary
Treatment of Leg Telangiectasias With Nd:YAG 1064nm
Showing all 4 trials